enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of “Buy” by Brokerages

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have been given an average rating of “Buy” by the eleven analysts that are currently covering the firm, Marketbeat.com reports. Ten investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $29.78.

ENGN has been the topic of a number of recent analyst reports. HC Wainwright started coverage on shares of enGene in a research report on Monday, December 23rd. They set a “buy” rating and a $25.00 price target on the stock. JMP Securities reiterated a “market outperform” rating and set a $18.00 target price on shares of enGene in a report on Monday, December 23rd. Raymond James began coverage on enGene in a report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 price target for the company. Finally, Citizens Jmp upgraded enGene to a “strong-buy” rating in a report on Monday, November 18th.

enGene Stock Down 5.6 %

Shares of enGene stock opened at $6.70 on Friday. enGene has a 12 month low of $4.42 and a 12 month high of $18.40. The business has a fifty day simple moving average of $7.32 and a 200 day simple moving average of $7.47. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08. The stock has a market cap of $296.27 million, a PE ratio of -11.55 and a beta of -0.65.

enGene (NASDAQ:ENGN) last announced its quarterly earnings results on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. Research analysts predict that enGene will post -1.57 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ENGN. Wolverine Asset Management LLC acquired a new position in enGene during the third quarter worth approximately $37,000. Vontobel Holding Ltd. bought a new stake in enGene in the 4th quarter valued at $69,000. Point72 Asset Management L.P. boosted its position in enGene by 1,410.3% during the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after purchasing an additional 619,100 shares during the period. Finally, Franklin Resources Inc. increased its holdings in shares of enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after purchasing an additional 389,918 shares during the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.